Scholarlink

Purpose <p>To evaluate the short-term efficacy and safety of finerenone in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD).</p> Methods <p>A retrospective cohort study was conducted on a relatively small sample of 23 patients diagnosed with T1D and CKD between January 2023 and August 2024. All patients received renin-angiotensin system inhibitors (RASi), with 12 patients additionally treated with finerenone.</p> Results <p>The cohort had a median age of 34 (29, 39) years, including 11 females. Median Hemoglobin A1c (HbA1c) was 7.30% (6.55, 8.10%), proteinuria was 1.49 (0.88, 2.84) g/24h, mean estimated glomerular filtration rate (eGFR) was 71.91 ± 24.59&#xa0;mL/min/1.73m<sup>2</sup>, and serum potassium was 4.47 ± 0.39 mmol/L. After 6 months of follow-up, eGFR declined significantly in the control group (−&#xa0;10.55 ± 14.61 mL/min/1.73m<sup>2</sup>, <i>P</i> = 0.038) but remained stable in the finerenone group (−&#xa0;1.34 ± 11.98 mL/min/1.73m<sup>2</sup>, <i>P</i> = 0.706). No significant changes were observed in proteinuria, serum potassium, blood pressure, or other metabolic parameters in either group. No cases of hyperkalemia or acute kidney injury (AKI) were observed among patients who completed the 6-month follow-up.</p> Conclusion <p>In this preliminary study, finerenone showed potential for attenuating kidney function decline in patients with T1D and CKD, though its long-term efficacy and safety require validation in larger trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights

  • 期刊论文

  • 发表日期：

    2025年9月5日

查看全文
  • Dandan Qiu,
  • Jingjing Wang,
  • Aijuan Li,
  • Wei Zhang,
  • Xiaofeng Du,
  • Genwang Wang,
  • Song Jiang

摘要

Purpose

To evaluate the short-term efficacy and safety of finerenone in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD).

Methods

A retrospective cohort study was conducted on a relatively small sample of 23 patients diagnosed with T1D and CKD between January 2023 and August 2024. All patients received renin-angiotensin system inhibitors (RASi), with 12 patients additionally treated with finerenone.

Results

The cohort had a median age of 34 (29, 39) years, including 11 females. Median Hemoglobin A1c (HbA1c) was 7.30% (6.55, 8.10%), proteinuria was 1.49 (0.88, 2.84) g/24h, mean estimated glomerular filtration rate (eGFR) was 71.91 ± 24.59 mL/min/1.73m2, and serum potassium was 4.47 ± 0.39 mmol/L. After 6 months of follow-up, eGFR declined significantly in the control group (− 10.55 ± 14.61 mL/min/1.73m2, P = 0.038) but remained stable in the finerenone group (− 1.34 ± 11.98 mL/min/1.73m2, P = 0.706). No significant changes were observed in proteinuria, serum potassium, blood pressure, or other metabolic parameters in either group. No cases of hyperkalemia or acute kidney injury (AKI) were observed among patients who completed the 6-month follow-up.

Conclusion

In this preliminary study, finerenone showed potential for attenuating kidney function decline in patients with T1D and CKD, though its long-term efficacy and safety require validation in larger trials.